-
Graybug Vision Reports Full Data Analysis After One Year Treatment Of GB-102 In Wet AMD
Wednesday, May 12, 2021 - 9:50am | 373Read More...Graybug Vision Inc (NASDAQ: GRAY) has provided full-data analysis from the 12-month treatment Phase of its Phase 2b ALTISSIMO trial evaluating GB-102 to treat wet age-related macular degeneration (wet AMD). GB-102 is a proprietary formulation of sunitinib malate injected twice...
-
Pfenex Inc. In Development Pact For Macular Degeneration Drug
Tuesday, February 10, 2015 - 1:07pm | 205Read More...Pfenex Inc (NYSE: PFNX) shares gained more than 20 percent after the company disclosed its macular degeneration drug candidate will get collaborative support from Hospira, Inc. (NYSE: HSP). San Diego-based Pfenex changed hands recently at $8.25, up $1.35. The drug under development is aimed at...
